胃非幽门螺杆菌螺杆菌属在胃病中的临床意义与影响
在幽门螺杆菌阴性的胃病患者中回顾性(n=464)和前瞻性(n=65)检测胃非幽门螺杆菌螺杆菌(NHPH),回顾性样本阳性率29.1%,对照未检出;前瞻性胃组织阳性率27.7%、唾液20.6%;根除治疗后17例中12例临床缓解。
要点
- 幽门螺杆菌阴性胃病患者中胃NHPH回顾性阳性率为29.1%,对照未检出。
- 前瞻性队列胃组织NHPH阳性率27.7%,唾液阳性率20.6%。
- 唾液检测胃NHPH的敏感度为27.8%、准确度为69.8%。
核心结论
- 这些发现提示NHPH可能参与胃病的病理生理过程。
- 有胃部症状的患者可能从常规PCR检测人畜共患胃NHPH中获益。
研究设计与样本
- 回顾性(n=464)和前瞻性(n=65)纳入幽门螺杆菌阴性的慢性胃炎、消化性溃疡病和胃MALT淋巴瘤患者,采集胃活检。
- 采用PCR和测序检测胃螺杆菌属。
- 回顾性纳入无症状胃旁路术患者(n=38)作为对照。
- 前瞻性额外采集唾液样本及症状和危险因素问卷。
- 前瞻性组中胃NHPH感染患者接受标准幽门螺杆菌根除治疗,治疗后行随访胃镜检查。
主要发现
- 回顾性样本中胃NHPH阳性率为29.1%,对照活检未检出胃NHPH。
- 前瞻性队列中胃组织阳性率为27.7%,唾液阳性率为20.6%。
- 唾液相比胃组织检测胃NHPH的敏感度为27.8%,准确度为69.8%。
- 根除治疗后,17例中12例记录到临床缓解,9例中7例组织学缓解,8例中4例根除。
临床怎么用
- 作者认为有胃部症状的患者可能从常规PCR检测人畜共患胃NHPH中获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gastric non-Helicobacter pylori Helicobacter (NHPH) species naturally associated with animals have been linked with gastric disease in human patients. AIM: The prevalence and clinical significance of zoonotic gastric NHPHs was determined in large and well-defined, H. pylori-negative, gastric patient populations. METHODS: Patients were retrospectively (n = 464) and prospectively (n = 65) included for gastric biopsy collection: chronic gastritis (CG), peptic ulcer disease and gastric MALT lymphoma, without identified aetiology. PCR and sequencing was performed for the detection of gastric Helicobacter species. Retrospectively, asymptomatic gastric bypass patients (n = 38) were included as controls. Prospectively, additional saliva samples and symptom and risk factor questionnaires were collected. In this group, patients with gastric NHPH infection were administered standard H. pylori eradication therapy and underwent follow-up gastroscopy post-therapy. RESULTS: In the retrospective samples, the prevalence of gastric NHPHs was 29.1%, while no gastric NHPHs were detected in control biopsies. In the prospective cohort, a similar proportion tested positive: 27.7% in gastric tissue and 20.6% in saliva. The sensitivity and accuracy for the detection of gastric NHPHs in saliva compared to gastric tissue was 27.8% and 69.8% respectively. Following eradication therapy, clinical remission was registered in 12 of 17 patients, histological remission in seven of nine and eradication in four of eight patients. CONCLUSION: These findings suggest a pathophysiological involvement of NHPHs in gastric disease. Patients presenting with gastric complaints may benefit from routine PCR testing for zoonotic gastric NHPHs.
引用
- Taillieu E, De Witte C, De Schepper H, et al. Clinical significance and impact of gastric non-Helicobacter pylori Helicobacter species in gastric disease. Aliment Pharmacol Ther. 2023. PMID: 36975151. doi:10.1111/apt.17488
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。